Form 4: Stoke Therapeutics GC Sells Shares Under 10b5-1 Plan

Stoke Therapeutics' General Counsel, Jonathan Allan, executed planned sales of common stock following option exercises.

Summary

• Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc., engaged in a series of equity transactions involving the company's common stock.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Allan on December 12, 2024.
• On August 29, 2025, Allan exercised stock options to acquire 850 shares at an exercise price of $7.07 per share and subsequently sold these 850 shares at a price of $20.00 per share.
• On September 2, 2025, Allan exercised stock options to acquire 9,150 shares at an exercise price of $7.07 per share.
• Also on September 2, 2025, Allan sold 14,922 shares at a weighted average price of $20.1375 per share, with individual transaction prices ranging from $20.00 to $20.40.
• On September 3, 2025, Allan sold an additional 6,345 shares at a weighted average price of $20.0657 per share, with individual transaction prices ranging from $20.00 to $20.20.
• Following these reported transactions, Allan's direct beneficial ownership of Stoke Therapeutics common stock decreased to 11,831 shares.
• The stock options exercised were part of an award that vests monthly, with 1/48th of the total award vesting from January 7, 2023, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic trading. The insider also realized a substantial profit, which is a positive for the individual.

Positives

• The reporting person realized a significant profit by exercising options at $7.07 per share and selling the acquired shares at prices ranging from $20.00 to $20.40 per share.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not opportunistic sale, which can be viewed favorably from a corporate governance perspective.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Risks

• There is a potential for negative market perception if investors misinterpret the planned insider selling as a lack of confidence in the company's future, despite the existence of a Rule 10b5-1 plan.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.
• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

Industry Context

This Form 4 filing details an individual insider's equity transactions and does not provide information directly related to broader industry trends or the competitive landscape. Such filings are common for executives managing their personal equity holdings, particularly when utilizing Rule 10b5-1 plans to avoid accusations of trading on material non-public information.

Comparison to Industry Standards

• Not applicable, as this filing pertains to individual insider trading activity rather than company performance metrics that can be benchmarked against industry peers or global standards.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be interpreted by some shareholders as a reduction in management's direct alignment with shareholder interests, though the 10b5-1 plan mitigates this concern.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions executed under a pre-arranged 10b5-1 trading plan. While the General Counsel is selling shares, the planned nature of these sales reduces concerns about a lack of confidence in the company's future. The filing itself does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should consider this as a standard disclosure of an executive managing personal equity holdings.

Keywords

Stoke Therapeutics, STOK, Jonathan Allan, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, General Counsel, Equity Transactions